Pseudogene KRT17P3 drives cisplatin resistance of human NSCLC cells by modulating miR‐497‐5p/mTOR

Zhibo Hou,Yi Wang,Ning Xia,Tangfeng Lv,Xiaoqin Yuan,Yong Song
DOI: https://doi.org/10.1111/cas.14733
IF: 5.7
2020-11-28
Cancer Science
Abstract:<p>Chemoresistance is a major obstacle in non‐small‐cell lung cancer (NSCLC) treatment. We previously showed the pseudogene Keratin 17 Pseudogene 3 (KRT17P3) has been shown to be up‐regulated in lung cancer tissues from patients with cisplatin resistance. In the present study, RT‐qPCR was performed to evaluate KRT17P3 levels in plasma samples collected from 30 cisplatin‐resistance patients and 32 cisplatin‐sensitive patients. We found that the plasma level of KRT17P3 is up‐regulated in cisplatin‐resistance patients and the increased expression of plasma KRT17P3 is associated with poor chemotherapy response. Functional studies demonstrated that KRT17P3 overexpression in cultured NSCLC cells increases cell viability and decreases apoptosis upon cisplatin treatment in vitro and in vivo, while KRT17P3 knockdown has the opposite effect. Mechanistically, bioinformatics analysis, RNA immunoprecipitation and dual luciferase reporter assay indicated that KRT17P3 acts as a molecular sponge for miR‐497‐5p and relieves the binding of miR‐497‐5p to its target gene mTOR. Rescue experiments validated the functional interaction among KRT17P3, miR‐497‐5p, and mTOR. Taken together, our findings indicate that KRT17P3/miR‐497‐5p/mTOR regulates the chemosensitivity of NSCLC, suggesting a potential therapeutic target for cisplatin‐resistant NSCLC patients. KRT17P3 may be a potential peripheral blood marker of NSCLC patients resistant to cisplatin.</p>
oncology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the molecular mechanism of non - small - cell lung cancer (NSCLC) resistance to cisplatin chemotherapy. Specifically, the study focused on the role of the pseudogene KRT17P3 in cisplatin resistance and its underlying molecular mechanisms. The study found that KRT17P3 drives cisplatin resistance in NSCLC cells by regulating the miR - 497 - 5p/mTOR pathway. ### Main research contents and methods 1. **Clinical sample analysis**: - Plasma samples from 62 NSCLC patients were collected, including 30 cisplatin - resistant patients and 32 cisplatin - sensitive patients. - RT - qPCR was used to detect the expression level of KRT17P3 in these samples. 2. **Cell experiments**: - By knocking down (shRNA - KRT17P3) and overexpressing (Lv - KRT17P3) KRT17P3, the effect on the cisplatin sensitivity of A549 and SK - MES - 1 cells was evaluated. - Cell viability was detected by the CCK - 8 method, cell apoptosis was detected by flow cytometry, and the cleavage level of PARP - 1 was detected by Western blot. 3. **Animal experiments**: - A549 cells with overexpressed KRT17P3 and control cells were injected subcutaneously into nude mice to establish a xenograft tumor model. - Through cisplatin treatment, the tumor growth was observed. 4. **Molecular mechanism research**: - Bioinformatics analysis was used to predict the binding sites between KRT17P3 and miR - 497 - 5p. - The interaction between KRT17P3 and miR - 497 - 5p was verified by the dual - luciferase reporter gene assay. - The direct binding between KRT17P3 and miR - 497 - 5p was further confirmed by the RNA immunoprecipitation (RIP) experiment. - The effect of miR - 497 - 5p on KRT17P3 - mediated cisplatin resistance was studied. ### Main results 1. **Up - regulation of KRT17P3 expression in the plasma of cisplatin - resistant patients**: - The plasma KRT17P3 level in cisplatin - resistant patients was significantly higher than that in cisplatin - sensitive patients. - TCGA database analysis showed that the expression of KRT17P3 in LUAD and LUSC tissues was also significantly up - regulated. 2. **KRT17P3 regulates the cisplatin sensitivity of NSCLC cells**: - Knocking down KRT17P3 increased the sensitivity of A549 and SK - MES - 1 cells to cisplatin, manifested as decreased cell viability and increased apoptosis. - Overexpressing KRT17P3 decreased the cell sensitivity to cisplatin, manifested as increased cell viability and decreased apoptosis. 3. **KRT17P3 affects cisplatin sensitivity by negatively regulating the miR - 497 - 5p/mTOR pathway**: - KRT17P3, as a molecular sponge of miR - 497 - 5p, reduces the binding of miR - 497 - 5p to its target gene mTOR. - Inhibiting the function of miR - 497 - 5p can reverse the increase in cisplatin sensitivity caused by knocking down KRT17P3. - Overexpressing miR - 497 - 5p can reverse the cisplatin resistance caused by overexpressing KRT17P3. ### Conclusion This study reveals the important role of KRT17P3 in cisplatin resistance of NSCLC cells by regulating the miR - 497 - 5p/mTOR pathway, providing a potential target for the development of new treatment strategies. KRT17P3 may become a peripheral blood marker for cisplatin - resistant NSCLC patients.